Takara L Stanley1, Meghan N Feldpausch1, Jinhee Oh1, Karen L Branch2, Hang Lee3, Martin Torriani4, Steven K Grinspoon1. 1. Program in Nutritional Metabolism and Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 2. Clinical Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 3. Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 4. Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Abstract
IMPORTANCE: Among patients infected with human immunodeficiency virus (HIV), visceral adiposity is associated with metabolic dysregulation and ectopic fat accumulation. Tesamorelin, a growth hormone-releasing hormone analog, specifically targets visceral fat reduction but its effects on liver fat are unknown. OBJECTIVE: To investigate the effect of tesamorelin on visceral and liver fat. DESIGN, SETTING, AND PATIENTS: Double-blind, randomized, placebo-controlled trial conducted among 50 antiretroviral-treated HIV-infected men and women with abdominal fat accumulation at Massachusetts General Hospital in Boston. The first patient was enrolled on January 10, 2011; for the final patient, the 6-month study visit was completed on September 6, 2013. INTERVENTIONS: Participants were randomized to receive tesamorelin, 2 mg (n=28), or placebo (n=22), subcutaneously daily for 6 months. MAIN OUTCOMES AND MEASURES: Primary end points were changes in visceral adipose tissue and liver fat. Secondary end points included glucose levels and other metabolic end points. RESULTS: Forty-eight patients received treatment with study drug. Tesamorelin significantly reduced visceral adipose tissue (mean change, -34 cm2 [95% CI, -53 to -15 cm2] with tesamorelin vs 8 cm2 [95% CI, -14 to 30 cm2] with placebo; treatment effect, -42 cm2 [95% CI, -71 to -14 cm2]; P = .005) and liver fat (median change in lipid to water percentage, -2.0% [interquartile range {IQR}, -6.4% to 0.1%] with tesamorelin vs 0.9% [IQR, -0.6% to 3.7%] with placebo; P = .003) over 6 months, for a net treatment effect of -2.9% in lipid to water percentage. Fasting glucose increased in the tesamorelin group at 2 weeks (mean change, 9 mg/dL [95% CI, 5-13 mg/dL] vs 2 mg/dL [95% CI, -3 to 8 mg/dL] in the placebo group; treatment effect, 7 mg/dL [95% CI, 1-14 mg/dL]; P = .03), but changes at 6 months in fasting glucose (mean change, 4 mg/dL [95% CI, -2 to 10 mg/dL] with tesamorelin vs 2 mg/dL [95% CI, -4 to 7 mg/dL] with placebo; treatment effect, 2 mg/dL [95% CI, -6 to 10 mg/dL]; P = .72 overall across time points) and 2-hour glucose (mean change, -1 mg/dL [95% CI, -18 to 15 mg/dL] vs -8 mg/dL [95% CI, -24 to 8 mg/dL], respectively; treatment effect, 7 mg/dL [95% CI, -16 to 29 mg/dL]; P = .53 overall across time points) were not significant. CONCLUSIONS AND RELEVANCE: In this preliminary study of HIV-infected patients with abdominal fat accumulation, tesamorelin administered for 6 months was associated with reductions in visceral fat and additionally with modest reductions in liver fat. Further studies are needed to determine the clinical importance and long-term consequences of these findings. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01263717.
RCT Entities:
IMPORTANCE: Among patients infected with human immunodeficiency virus (HIV), visceral adiposity is associated with metabolic dysregulation and ectopic fat accumulation. Tesamorelin, a growth hormone-releasing hormone analog, specifically targets visceral fat reduction but its effects on liver fat are unknown. OBJECTIVE: To investigate the effect of tesamorelin on visceral and liver fat. DESIGN, SETTING, AND PATIENTS: Double-blind, randomized, placebo-controlled trial conducted among 50 antiretroviral-treated HIV-infectedmen and women with abdominal fat accumulation at Massachusetts General Hospital in Boston. The first patient was enrolled on January 10, 2011; for the final patient, the 6-month study visit was completed on September 6, 2013. INTERVENTIONS:Participants were randomized to receive tesamorelin, 2 mg (n=28), or placebo (n=22), subcutaneously daily for 6 months. MAIN OUTCOMES AND MEASURES: Primary end points were changes in visceral adipose tissue and liver fat. Secondary end points included glucose levels and other metabolic end points. RESULTS: Forty-eight patients received treatment with study drug. Tesamorelin significantly reduced visceral adipose tissue (mean change, -34 cm2 [95% CI, -53 to -15 cm2] with tesamorelin vs 8 cm2 [95% CI, -14 to 30 cm2] with placebo; treatment effect, -42 cm2 [95% CI, -71 to -14 cm2]; P = .005) and liver fat (median change in lipid to water percentage, -2.0% [interquartile range {IQR}, -6.4% to 0.1%] with tesamorelin vs 0.9% [IQR, -0.6% to 3.7%] with placebo; P = .003) over 6 months, for a net treatment effect of -2.9% in lipid to water percentage. Fasting glucose increased in the tesamorelin group at 2 weeks (mean change, 9 mg/dL [95% CI, 5-13 mg/dL] vs 2 mg/dL [95% CI, -3 to 8 mg/dL] in the placebo group; treatment effect, 7 mg/dL [95% CI, 1-14 mg/dL]; P = .03), but changes at 6 months in fasting glucose (mean change, 4 mg/dL [95% CI, -2 to 10 mg/dL] with tesamorelin vs 2 mg/dL [95% CI, -4 to 7 mg/dL] with placebo; treatment effect, 2 mg/dL [95% CI, -6 to 10 mg/dL]; P = .72 overall across time points) and 2-hour glucose (mean change, -1 mg/dL [95% CI, -18 to 15 mg/dL] vs -8 mg/dL [95% CI, -24 to 8 mg/dL], respectively; treatment effect, 7 mg/dL [95% CI, -16 to 29 mg/dL]; P = .53 overall across time points) were not significant. CONCLUSIONS AND RELEVANCE: In this preliminary study of HIV-infectedpatients with abdominal fat accumulation, tesamorelin administered for 6 months was associated with reductions in visceral fat and additionally with modest reductions in liver fat. Further studies are needed to determine the clinical importance and long-term consequences of these findings. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01263717.
Authors: A M Kriska; W C Knowler; R E LaPorte; A L Drash; R R Wing; S N Blair; P H Bennett; L H Kuller Journal: Diabetes Care Date: 1990-04 Impact factor: 19.112
Authors: Martin Torriani; Bijoy J Thomas; Elkan F Halpern; Megan E Jensen; Daniel I Rosenthal; William E Palmer Journal: Radiology Date: 2005-08 Impact factor: 11.105
Authors: Polyxeni Koutkia; Bridget Canavan; Jeff Breu; Martin Torriani; John Kissko; Steven Grinspoon Journal: JAMA Date: 2004-07-14 Impact factor: 56.272
Authors: Marshall J Glesby; Jeanine Albu; Ya-Lin Chiu; Kirsis Ham; Ellen Engelson; Qing He; Varalakshmi Muthukrishnan; Henry N Ginsberg; Daniel Donovan; Jerry Ernst; Martin Lesser; Donald P Kotler Journal: PLoS One Date: 2013-04-12 Impact factor: 3.240
Authors: Roger Bouillon; Daniel J Drucker; Ele Ferrannini; Steven Grinspoon; Clifford J Rosen; Paul Zimmet Journal: Nat Rev Endocrinol Date: 2015-09-01 Impact factor: 43.330
Authors: S Adrian; A Scherzinger; A Sanyal; J E Lake; J Falutz; M P Dubé; T Stanley; S Grinspoon; J-C Mamputu; C Marsolais; T T Brown; K M Erlandson Journal: J Frailty Aging Date: 2019
Authors: Takara L Stanley; Lindsay T Fourman; Meghan N Feldpausch; Julia Purdy; Isabel Zheng; Chelsea S Pan; Julia Aepfelbacher; Colleen Buckless; Andrew Tsao; Anela Kellogg; Karen Branch; Hang Lee; Chia-Ying Liu; Kathleen E Corey; Raymond T Chung; Martin Torriani; David E Kleiner; Colleen M Hadigan; Steven K Grinspoon Journal: Lancet HIV Date: 2019-10-11 Impact factor: 12.767
Authors: Lindsay T Fourman; Natalia Czerwonka; Meghan N Feldpausch; Julian Weiss; Jean-Claude Mamputu; Julian Falutz; Josée Morin; Christian Marsolais; Takara L Stanley; Steven K Grinspoon Journal: AIDS Date: 2017-10-23 Impact factor: 4.177
Authors: Laurie R Braun; Meghan N Feldpausch; Natalia Czerwonka; Martin Torriani; Steven K Grinspoon; Takara L Stanley Journal: Growth Horm IGF Res Date: 2017-10-07 Impact factor: 2.372